CAS: 2443767-35-7
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | BPR1K871 REF: IN-DA01TP4JCAS: 2443767-35-7 | 98% | To inquire | Tue 07 Jan 25 |
 | BPR1K871 REF: TM-T10592CAS: 2443767-35-7 | - - - | 1,161.00 €~1,994.00 € | Tue 07 Jan 25 |
 | BPR1K871 REF: 3D-TXD76735CAS: 2443767-35-7 | Min. 95% | To inquire | Tue 18 Feb 25 |
Ref: IN-DA01TP4J
| 1mg | To inquire | ||
| 5mg | To inquire |
Estimated delivery in United States, on Tuesday 7 Jan 2025
BPR1K871
CAS:2443767-35-7
BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor …
Formula:
C25H28ClN7O2S
Color and Shape:
Solid
Molecular weight:
526.05
Ref: TM-T10592
| 10mg | 1,161.00 € | ||
| 25mg | 1,994.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
BPR1K871
CAS:2443767-35-7
BPR1K871 is a synthetic, orally bioavailable anticancer compound that has potent anticancer activity. It is …
Formula:
C25H28ClN7O2S
Purity:
Min. 95%
Molecular weight:
526.1 g/mol
Ref: 3D-TXD76735
| 1mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
